CYP 2.08% 23.5¢ cynata therapeutics limited

Shaw and Partners Research Update, page-15

  1. 1,585 Posts.
    lightbulb Created with Sketch. 632
    Yes, like it.

    So $400M MC based on GvHD alone sounds about right. That's a 3x current MC for a SP=$4 (give or take with oppie conversion).

    Now CLI say 4 x bigger. That's another $16/sh. So we are talking $20/sh potential if we see it out to become a licensing company, just for these 2 indications let alone the others in the pipeline.

    Other indications,....... you get the picture.
 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.